Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

554
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
554
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

219
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
219
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

927
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
927
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

45
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
45
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

2.1K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
2.1K
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

4.0K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protective Effects of Mussaenda pubescens Leaf Extracts Against Oxidative Stress and Dyslipidemia.

BioMed research international·2026
Same author

Antioxidant Capacity Alterations in Bangladeshi Underutilized Fruits: InsightsFrom In Vitro Gastrointestinal Digestion Studies.

International journal of food science·2026
Same author

Enhanced hemostasis and bone regeneration achieved by thrombin-simvastatin-polydopamine loaded spray-dried β-TCP/ gelatin/ soy protein isolate biocomposites in critical rat calvarial defects.

Materials today. Bio·2026
Same author

Upper Arm to Upper Leg Length Ratio and Dyslipidemia: A Novel Application of a Fixed Skeletal Proportion Metric in a Nationally Representative U.S. Sample.

International journal of environmental research and public health·2026
Same author

The CHRONO trial: Protocol for a randomized controlled trial of early time-restricted eating in patients with breast or rectal cancer.

Nutrition research (New York, N.Y.)·2026
Same author

Palbociclib in Patients With HR+/HER2- Advanced or Metastatic Breast Cancer and Bone-Only Metastasis: A Systematic Literature Review.

Clinical breast cancer·2026

Related Experiment Video

Updated: Aug 22, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K

Beta-Blocker-Induced Erythrodermic Psoriasis: A Case Report.

Diana Voloshyna1, Saad Ehsan Ullah2, Nusrat Jahan3

  • 1School of Medicine, University of Michigan, Ann Arbor, USA.

Cureus
|November 7, 2022
PubMed
Summary

Beta-blockers, commonly used for heart conditions, can paradoxically trigger severe skin reactions like erythrodermic psoriasis. This case highlights a rare side effect, emphasizing the need for vigilant monitoring in patients using these cardiovascular drugs.

Keywords:
beta-blockerbeta-blocker-induced psoriasiscase reportdrug-induced psoriasiserythrodermic psoriasispsoriasis

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.6K
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.0K

Related Experiment Videos

Last Updated: Aug 22, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.0K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.6K
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
07:50

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts

Published on: September 20, 2018

16.0K

Area of Science:

  • Dermatology
  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are widely prescribed for cardiovascular conditions.
  • Common side effects include hypoglycemia, dizziness, bradycardia, fatigue, and heart block.
  • Physicians are generally aware of these known adverse effects.

Observation:

  • A 61-year-old woman with no prior history of psoriasis developed erythrodermic psoriasis.
  • The patient was taking beta-blockers for cardiac disease.
  • The diagnosis was confirmed via histopathology and a Naranjo score of 6.

Findings:

  • Beta-blockers were identified as the causative agent for erythrodermic psoriasis.
  • The patient was treated with weekly methotrexate (15 mg) and supportive care.
  • Complete recovery from the skin condition was achieved within two months.

Implications:

  • This case underscores a rare but significant adverse drug reaction associated with beta-blockers.
  • Highlights the importance of considering drug-induced conditions in dermatological diagnoses.
  • Suggests the need for increased awareness among clinicians regarding potential skin manifestations of beta-blocker therapy.